Azmiro first prefilled testosterone cypionate injection approved by the FDA now available in US

madman

Super Moderator


The therapy is the first and only prefilled testosterone cypionate injection approved by the FDA.

Testosterone replacement therapy Azmiro is now available in the United States for use in male patients who have conditions that are associated with a deficiency or absence of endogenous testosterone, Azurity Pharmaceuticals announced in a release.1 The therapy is the first and only prefilled testosterone cypionate injection approved by the FDA.

Azmiro comes as a 200 mg/mL single dose syringe and is intended for intramuscular use. This prefilled option provides greater accuracy and safety by reducing the potential for inadvertent needle sticks and exposure to products while drawing from a vial, as well as a reduced risk of microbial contamination. The safety and efficacy of Azmiro has not been established in men with age-related hypogonadism.

“Azurity’s purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs,” Richard Blackburn, CEO of Azurity, said in a release.1 “The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients.”

Testosterone deficiency, also known as hypogonadism, impacts between 20% to 50% of males in the US.2 The condition increases with age, with a particular rise in men aged 45 to 50 years. Low testosterone can also be caused by some conditions, including Klinefelter syndrome, mumps orchitis, and undescended testicles. Testosterone deficiency can lead to low energy, depression, poor concentration, low libido, and erectile dysfunction.

Testosterone replacement therapy has shown to improve the symptoms of hypogonadism and overall quality of life in patients with low serum testosterone.3 Research has shown that it can improve sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, and cognition. Although testosterone replacement therapy does come with a potential risk for adverse events, it remains a safe and beneficial options for patients.
 
2 extremes here, all those endos still dishing out those outdated protocols or those dime a dozen run of the mil T-clinics overmedicating all those poor chaps from the get-go!

LOL!


1740807279247.webp

1740807310620.webp

1740807343102.webp

1740807412602.webp

1740807456962.webp

1740808223144.webp
 
2 injections per month of TC, now we call it Azmiro
Similar to TU every 12 weeks is called Nebido.
What about the syringe? Is it a special applicator? I don't see any needle.
Ok, looked in the attachment, it's a luer lock and one has to attach the needle.

"
Important Administration Information  The prefilled syringe should be administered as an intramuscular injection by a healthcare professional only.  The prefilled syringe should only be used to administer doses of 200 mg. For administration of doses other than 200 mg, use the AZMIRO single-dose vial.  AZMIRO 200 mg/mL is supplied as single-dose prefilled syringe with luer lock connector.  The prefilled syringe carton does not contain a needle. Obtain suitable needle separately.
"
That's really a joke.
 
Last edited:

Online statistics

Members online
4
Guests online
395
Total visitors
399

Latest posts

Back
Top